Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Frontline Lenalidomide for AL Amyloidosis Involving Myocardium

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04298372
Recruitment Status : Recruiting
First Posted : March 6, 2020
Last Update Posted : March 6, 2020
Sponsor:
Information provided by (Responsible Party):
Youngil Koh, Seoul National University Hospital

Brief Summary:
This phase II clinical trial aimed at influencing the improvement of major organ functions, especially the objective response rate, in Amyloid light-chain amyloidosis involving myocardium.

Condition or disease Intervention/treatment Phase
Amyloidosis Cardiac Drug: Lenalidomide 25mg Phase 3

Detailed Description:

This study was designed according to the 18F-florbetaben positron emission tomography imaging, which successfully demonstrated a significant reduction in the amount of amyloid in the heart when administered by merging thalidomide and dexamethasone in patients involving myocardium, and reported that this reaction leads to an improvement in cardiac function. Amyloid light-chain amyloidosis patients at age 19 or older with refractory or relapsed who participants should have never been exposed to lenalidomide within 5 years. Planned initial dosage of the current regimen are as follow;

  • Lenalidomide : D1~D21 daily oral administration, starting dose 15mg, with an increase of 5mg every cycle, if tolerated, up to 25mg.
  • Dexamethasone : D1~D4 daily oral administration or intravenous injection, 40mg(or 20mg for age for age ≥ 65 years old) Patients will be treated every 4 weeks as one cycle, and up to 12 cycles of treatment will be conducted. The investigator is working on a total of 30 patients, the primary endpoint of this study is objective response rate and secondary endpoints are cardiac/renal/hepatic function, 18F-florbetaben positron emission tomography imaging parameter, overall survival period, progression-free survival period, toxicity profile.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Frontline Lenalidomide for AL Amyloidosis Involving Myocardium: Investigation of Organ Reversing Capacity of Lenalidomide
Actual Study Start Date : February 20, 2019
Estimated Primary Completion Date : March 15, 2021
Estimated Study Completion Date : December 31, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Amyloidosis


Intervention Details:
  • Drug: Lenalidomide 25mg

    As single arm study, patients will be treated as follows:

    • Lenalidomide : D1~D21 daily oral administration, starting dose 15mg, with an increase of 5mg every cycle, if tolerated, up to 25mg.
    • Dexamethasone : D1~D4 daily oral administration or intravenous injection, 40mg(or 20mg for age for age ≥ 65 years old) Patients will be treated every 4 weeks as one cycle, and up to 12 cycles of treatment will be conducted.
    Other Name: Revlimid 25mg


Primary Outcome Measures :
  1. Objective response rate (ORR) [ Time Frame: After completion of 12 cycles of treatment(each cycle is 28 days) ]
    ORR is defined as the percentage of subjects with evidence of a confirmed CR(complete response), VGPR(very good partial response) or PR(partial response)


Secondary Outcome Measures :
  1. Change of the cardiac function [ Time Frame: At Baseline and the end of each 1-12 cycles (baseline and 1-12 months) ]
    Change of the cardiac function will be observed with the NTproBNP levels.

  2. Change of the renal function [ Time Frame: At Baseline and the end of each 1-12 cycles (baseline and 1-12 months) ]
    Change of the renal function will be observed with the 24h urine protein levels.

  3. Change of the hepatic function [ Time Frame: At Baseline and the end of each 1-12 cycles (baseline and 1-12 months) ]
    Change of the hepatic function will be observed with the alkaline phophatase levels.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   19 Years to 99 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age more than 19 years old
  • Amyloid light-chain amyloidosis patients who meet both(A and B) of the following criteria

A. Cardiac involvement: meet one or more of the following criteria

  1. Echocardiography : mean wall thickness > 12mm, and no other cardiac cause
  2. Cardiac MRI : CMR was considered positive for amyloid cardiomyopathy if there were morphologic and structural abnormalities consistent with the diagnosis (wall thickening of the left ventricular [LV], right ventricular [RV], or interatrial septum and biatrial enlargement) coupled with abnormal myocardial nulling and diffuse or irregular delayed gadolinium enhancement of the LV myocardium.
  3. N-terminal prohormone of brain natriuretic peptide : > 332ng/l in the absence pf renal failure

B. Exposure history to lenalidomide: participants should have never been exposed to lenalidomide within 5 years.

  • Eastern Cooperative Oncology Group performance status ≤ 3
  • Patients must meet the following clinical laboratory criteria with 2 weeks of starting treatment:

    1. Serum creatinine ≤ 3.0mg/dl or Creatinine Clearance ≥ 50ml/minute (Cockcroft-Gault)
    2. Absolute neutrophil count ≥ 1000/ul
    3. Platelet ≥ 75,000/ul
    4. Hemoglobin ≥ 8.0mg/dl
    5. Bilirubin < 2 times or Alkaline phosphate < 4 times upper limit of normal
  • At least 3 months of existence are expected from the time of enroll this study
  • A female of childbearing potential(is defined as a sexually mature woman who: 1 has not undergone a hysterectomy or bilateral oophorectomy or 2, has not been naturally post-menopausal (amenorrhea following cancer therapy does not rule out childbearing potential) must have a negative pregnancy test prior to treatment.

    1. must agree to use two reliable methods of contraception simultaneously or practice complete abstinence from any heterosexual intercourse during the following time periods related to this study: for at least 4 weeks after study treatment discontinuation.
    2. must have two(serum and urine) negative pregnancy test during screening period
    3. must have serum and urine negative pregnancy test within 10-14 days and 24hrs before commencing lenalidomide
  • Male patients who agree to practice effective barrier contraception during the entire study treatment period and through 30 days after the last dose of study treatment
  • Patients who understand and voluntarily agree to the contents of the research statement in writing and who are willing and able to comply with the visit schedule, treatment plan, laboratory examination and other testing procedures

Exclusion Criteria:

  • Amyloid light-chain amyloidosis without cardiac involvement
  • Patients who are planning to receive autologous stem cell transplantation or received autologous stem cell transplantation, remained in hematologic complete response
  • Pregnant, lactating or unwilling to use adequate contraception
  • Male patients who unwilling to practice effective barrier contraception during the entire study treatment period and through 30 days after the last dose of study treatment
  • Patients with acute infections requiring nonpermanent therapy (antibiotics, antibacterial drugs, or antiviral drugs) within 14 days of the first administration of the lenalidomide or with a history of systemic fungal infections and infections without valid antimicrobial agents
  • Any clinically significant history of genetic, kidney, neurological, psychiatric, endocrine, metabolism, immunological, cardiovascular, lung, or liver diseases in the investigator's opinion, may interfere with protocol adherence or a patient's ability to give informed consent.
  • Patients with known history of allergic and hypersensitivity for investigational product, their analogous bodies, or the subtypes contained in the various forms of any preparation
  • Patients who were given a live vaccine within 8 weeks of the first dose of the drug
  • Chemotherapy with approved or investigation anticancer therapeutics within 4 weeks prior to starting this study
  • Patients who are unable to voluntarily agree to participate in a study or who are not willing to participate

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04298372


Contacts
Layout table for location contacts
Contact: Youngil Koh, MD 82220727217 snuhgo01@gmail.com
Contact: Juhyun Lee, CRC 82220724999 lee-jh8368@daum.net

Locations
Layout table for location information
Korea, Republic of
Seoul National University Hospital Recruiting
Seoul, Korea, Republic of, 03080
Contact: Youngil Koh, MD    82220727217    snuhgo01@gmail.com   
Sponsors and Collaborators
Seoul National University Hospital
Investigators
Layout table for investigator information
Principal Investigator: Youngil Koh, MD Seoul National University Hospital
Layout table for additonal information
Responsible Party: Youngil Koh, Assistant Professor, Seoul National University Hospital
ClinicalTrials.gov Identifier: NCT04298372    
Other Study ID Numbers: 1810-089-981
First Posted: March 6, 2020    Key Record Dates
Last Update Posted: March 6, 2020
Last Verified: March 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Immunoglobulin Light-chain Amyloidosis
Amyloidosis
Proteostasis Deficiencies
Metabolic Diseases
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Paraproteinemias
Lenalidomide
Immunologic Factors
Physiological Effects of Drugs
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Growth Inhibitors
Antineoplastic Agents